I-Ming Wang
Director - Translational Oncology Pfizer
I-Ming Wang is Director, Translational Oncology at Pfizer, a role held since August 2017. Previously, he spent a decade at Merck, most recently as Immuno-oncology Biomarker Lead, and held earlier roles at Merck Research Lab/Rosetta and Wyeth.
Seminars
Friday 19th March 2027
Panel Discussion: Detecting & Tracking Acquired Resistance Mutations to Expedite Clinical Decision-Making
2:00 pm
- Establishing monitoring intervals frequent enough to catch resistance emergence before clinical progression
- Distinguishing true resistance signal from clonal noise to avoid switching therapy on a false trigger
- Building switch criteria into protocols so molecular progression is an actionable endpoint, not an observation
